Wellington Management Group LLP Has $5.47 Million Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• Wellington Management Group LLP has increased its stake in Exelixis, Inc. by 7.1%, owning approximately 148,198 shares valued at $5.47 million after purchasing additional shares in the first quarter.
• Exelixis reported $0.75 EPS for the last quarter, surpassing analysts' expectations of $0.63, although its quarterly revenue fell by 10.8% year-over-year.
• Several analysts have provided a range of target prices for Exelixis stock, with a consensus target price of $44.06 and a rating of "Moderate Buy".

Wellington Management Group LLP boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,198 shares of the biotechnology company's stock after buying an additional 9,790 shares during the period. Wellington Management Group LLP owned about 0.05% of Exelixis worth $5,471,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Exelixis during the 1st quarter valued at $123,310,000. Caisse DE Depot ET Placement DU Quebec increased its position in Exelixis by 330.4% in the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock worth $82,730,000 after purchasing an additional 1,907,167 shares during the period. Invesco Ltd. raised its holdings in Exelixis by 40.2% during the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the last quarter. Jupiter Asset Management Ltd. raised its stake in shares of Exelixis by 233.4% during the first quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company's stock worth $51,698,000 after buying an additional 980,319 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Exelixis in the fourth quarter valued at approximately $30,321,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Price Performance

EXEL stock traded down $0.10 during midday trading on Wednesday, reaching $37.08. The company had a trading volume of 1,228,019 shares, compared to its average volume of 3,016,286. Exelixis, Inc. has a 1-year low of $25.12 and a 1-year high of $49.62. The company has a market capitalization of $9.98 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32. The stock has a 50 day moving average price of $40.97 and a 200-day moving average price of $39.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on EXEL. Bank of America increased their price target on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research report on Thursday, June 5th. William Blair reissued an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. Barclays raised their price target on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 10th. UBS Group set a $38.00 price objective on Exelixis and gave the company a "neutral" rating in a research report on Wednesday, July 30th. Finally, Jefferies Financial Group set a $50.00 target price on Exelixis and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Thirteen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Exelixis currently has an average rating of "Moderate Buy" and a consensus target price of $44.06.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.